Literature DB >> 9642098

An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.

D A Persons1, M G Mehaffey, M Kaleko, A W Nienhuis, E F Vanin.   

Abstract

Most retroviral vectors used in preclinical and clinical studies contain a selectable marker gene to facilitate the generation of producer clones. However, the expression of such genes in target cells is often undesirable since this may modify cellular phenotype and invoke a host immune response. Unfortunately, the efficient identification of high-titer producer clones for vectors lacking a selectable marker gene continues to be problematic and lacking for a standard methodology. Despite recent improvements in the screening techniques for identifying high-titer producer clones without the aid of a selectable marker, a solution to the fundamental problem of the very low frequency occurrence of high-titer clones within the starting cell population has not emerged. We have developed a strategy which greatly increases the frequency of virus-producing clones, including those with high-titer, within the population of transduced cells to be screened. This approach relies on the use of high-titer vector preparations generated in 293T cells by co-transfection of retroviral packaging and vector plasmids. Viral preparations of a vector lacking a selectable marker were used to repeatedly transduce exponentially growing packaging cells at a high multiplicity of infection (MOI). Each cell in the resulting polyclonal population of producer cells contained multiple copies of the unrearranged vector genome. Greater than 95% of the clones derived from this population produced vector particles as judged by slot blot analysis of viral RNA from conditioned media. Numerous clones with estimated titers of 10(5)-10(6) were identified. These titers were confirmed using a standard vector genome transmission assay. This approach significantly enhances the ability, without large scale screening, to easily identify high-titer clones lacking a selectable marker and should facilitate the routine use of simplified gene marking and therapeutic vectors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9642098     DOI: 10.1006/bcmd.1998.0184

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  24 in total

1.  Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development.

Authors:  R Wen; D Wang; C McKay; K D Bunting; J C Marine; E F Vanin; G P Zambetti; S J Korsmeyer; J N Ihle; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

2.  Suppression of E1A-mediated transformation by the p50E4F transcription factor.

Authors:  E R Fernandes; R J Rooney
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

3.  High-throughput selection of retrovirus producer cell lines leads to markedly improved efficiency of germ line-transmissible insertions in zebra fish.

Authors:  Wenbiao Chen; Shawn Burgess; Greg Golling; Adam Amsterdam; Nancy Hopkins
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation.

Authors:  M Kieslinger; I Woldman; R Moriggl; J Hofmann; J C Marine; J N Ihle; H Beug; T Decker
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

5.  Exploring the functional complexity of cellular proteins by protein knockout.

Authors:  Jianxuan Zhang; Ning Zheng; Pengbo Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205

6.  Distinct domains of erythroid Krüppel-like factor modulate chromatin remodeling and transactivation at the endogenous beta-globin gene promoter.

Authors:  R Clark Brown; Scott Pattison; Janine van Ree; Elise Coghill; Andrew Perkins; Stephen M Jane; John M Cunningham
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

7.  Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study.

Authors:  Chi-Ping Day; John Carter; Carrie Bonomi; Dominic Esposito; Bruce Crise; Betty Ortiz-Conde; Melinda Hollingshead; Glenn Merlino
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-19       Impact factor: 4.693

8.  An in vitro system for studying murid herpesvirus-4 latency and reactivation.

Authors:  Janet S May; Neil J Bennett; Philip G Stevenson
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

9.  N-terminal polyubiquitination and degradation of the Arf tumor suppressor.

Authors:  Mei-Ling Kuo; Willem den Besten; David Bertwistle; Martine F Roussel; Charles J Sherr
Journal:  Genes Dev       Date:  2004-08-01       Impact factor: 11.361

10.  In vivo imaging of murid herpesvirus-4 infection.

Authors:  Ricardo Milho; Christopher M Smith; Sofia Marques; Marta Alenquer; Janet S May; Laurent Gillet; Miguel Gaspar; Stacey Efstathiou; J Pedro Simas; Philip G Stevenson
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.